BioLife Solutions, Inc. ( BLFS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - CEO & Chairman Conference Call Participants Paul Knight - KeyBanc Capital Markets Inc., Research Division Matthew Stanton - Jefferies LLC, Research Division Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2025 Shareholder and Analyst Conference Call.
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.02 per share a year ago.
After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses which it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Roderick de Greef CEO | XDUS Exchange | US09062W2044 ISIN |
| US Country | 159 Employees | - Last Dividend | 29 Jan 2014 Last Split | 22 Nov 1989 IPO Date |
BioLife Solutions, Inc. is a pivotal entity within the cell and gene therapy (CGT) sector, offering a comprehensive suite of bioproduction tools and services. Established in 1987 and based in Bothell, Washington, this company caters to a global market, including the United States, Europe, the Middle East, and Africa. BioLife Solutions plays a critical role in both the research and commercial manufacturing of biologic-based therapies, addressing the needs of the rapidly evolving CGT industry by developing, manufacturing, and marketing a wide range of products designed to enhance the preservation, growth, and viability of cellular materials.
The offerings of BioLife Solutions are diversified and tailored to meet the specific requirements of the CGT domain. These include:
These proprietary biopreservation media products are engineered to reduce preservation-induced, delayed-onset cell damage and death, thereby enhancing the viability and functional integrity of cellular and gene therapies during the freezing, storage, and transportation processes.
An essential tool for the cell therapy sector, these lysates facilitate the expansion and growth of therapeutic cells, providing a superior alternative to traditional fetal bovine serum.
Designed for the CGT market, these vials offer a secure method for the containment and transport of cellular products, ensuring product integrity and regulatory compliance.
This family of devices is specifically developed for thawing frozen cell and gene therapies packaged in cryovials and cryobags, offering standardized, rapid, and reproducible thawing to ensure maximum viability of thawed materials.
Includes controlled rate freezing and cryogenic storage solutions for biologic materials, ensuring long-term preservation of cellular and biomolecular integrity at ultra-low temperatures.
These freezers provide dependable, energy-efficient storage options for sensitive biological materials and pharmaceuticals, maintaining optimal conditions for long-term viability.
Cloud-connected passive storage and transport containers designed for temperature-sensitive biologics and pharmaceuticals, offering real-time monitoring to ensure product integrity during transit.
A comprehensive range of products for the storage and handling of cryogenically preserved biological samples, offering solutions for every stage of the cryopreservation process.
Providing end-to-end logistic solutions for the CGT sector, these services ensure the safe, compliant, and efficient transport and storage of sensitive biological materials and pharmaceuticals.
BioLife Solutions markets and sells its products both directly and through third-party distributors, ensuring widespread availability and support for its comprehensive suite of bioproduction tools and services.